The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Clinical Protein Science and Targeted Mass Spectrometric Assays - New Frontiers in Disease Link and Biobanking

På svenska

Author

Editor

  • Joshua LaBaer
  • Manuel Fuentes

Summary, in English

Today’s societies have to reach out for improved healthcare solutions due to the increased number of patients and changed disease profiles represented by the dominance of cardiovascular and neurodegenerative diseases as well as various forms of cancer that require customized therapies. There is an extensive need for diagnostic and therapeutic biomarkers that may also become targets for drug developments in the future. Modern analytical platforms headed by mass spectrometry offer enhanced sensitivity as well as novel methodologies with extreme specificity to identify and quantify these potential protein markers in clinical studies, which is in the focus of international research organized by the Human Proteome Organization. However, the complexity of clinical samples and the wide concentration range of proteins represent analytical tasks yet need to be accomplished. In this chapter we present the challenges the healthcare systems face nowadays and outline possible solutions using biobanking standardization, personalized medicine and mass spectrometric technologies with relevant examples.

Publishing year

2014

Language

English

Pages

157-173

Publication/Series

Proteomics: Targeted Technology, Innovations and Applications

Document type

Book chapter

Publisher

Horizon Scientific Press

Topic

  • Medical Engineering

Status

Published

ISBN/ISSN/Other

  • ISBN: 978-1-908230-46-1